Contact Us     Privacy Policy     Terms of Use                                                                                  © Copyright Pharma CI Conference & Exhibition.  All Rights Reserved.
PROGRAM AGENDA:                                                                   
DAY 1 (Tuesday, September 21, 2010)
General Session:
7:15-8:15
 Registration & Networking Breakfast in Exhibition Hall

__________________________________________________________________________________________________________________________________
8:15-8:30
 Conference Chairpersons’ Opening Remarks

Co-Chair: Dr. Daniel Pascheles
Vice President, Head Global Competitive Intelligence, Merck & Co

Co-Chair: Sue Ward
Senior Director, Worldwide Competitive Intelligence, Pfizer

__________________________________________________________________________________________________________________________________
8:30-9:00
 Impacts of Pharma 2.0
Program around three interacting elements that will be shaping the basic business model of the future, not just R&D but commercialization as well:  Healthcare
Infrastructure Technology (HIT) and the related topic of Healthcare Information Exchange (HIE) as key enablers of Evidence-based Medicine (EBM) and its current
embodiment, Comparative Effectiveness (CER), and Personalized Healthcare (PHC).  Key questions: How do we move toward a Learning Healthcare System that is
truly patient-centric?  and what role does pharma play in that transition?  To be provocative, I might suggest that big pharma, the way it is currently configured, plays
no role in that world implying that a different model will appear.  Are the attendees companies prepared for such a new world?

Wayne A. Rosenkrans, Jr., Ph.D.
Distinguished Fellow, MIT Center for Biomedical Innovation
Program in Ethics and Systems Medicine, Georgetown University
Chairman and President, Personalized Medicine Coalition
VP Strategic Consulting, Fuld and Co.
Chief Applications Officer, SciTech Strategies

__________________________________________________________________________________________________________________________________
9:00-10:00
 R&D Models for a New Era
The pharmaceutical world that has been long predicted and somewhat feared is now upon us. The cliff is in clear view and is casting a sobering shadow on pharma
analysts' models. When put to forecasted numbers the industry is entering an unprecedented period of low growth both in terms of revenue and profitability. The
analysts' conclusion is a rude awakening and call to action: the pharmaceutical business model is broken, and is not sustainable, and today, new thinking is not just a
nice-to-do, it is absolutely required. The R&D expense line is no exception. Pharma companies are asking "are there better ways to innovate and develop the next
generation of drugs?" The clearest trend is that large companies are evermore externalizing their R&D activities and taking advantage of innovation, technologies,
and drug development efficiencies that lie outside the company walls.

Our expert panel of invited speakers has first-hand experience with the R&D issues that affect the future of pharmaceutical Research and Development:

Moderator:
Mark Little
Vice President, Business Intelligence & Market Research, Covance
Former President of the Society of Competitive Intelligence Professionals

Panelists:
Michael D. Taylor, Ph.D.
President & CEO, Ensemble Discovery Corp.

Aaron Schacht
Executive Director/COO - Global External R&D, Eli Lilly

Roland Andersson
Senior Managing Director, Strategic Advisors, Leerink Swann & Co

__________________________________________________________________________________________________________________________________
10:00-11:00
 Networking & Refreshments in Exhibition Hall

__________________________________________________________________________________________________________________________________
11:00-11:30
 How to Effectively Integrate CI in Business-Planning for Maximum Competitive Gain
This presentation will detail how CI can play an integral and strategic role in business planning. It outlines the necessary steps for building such capabilities and
pinpoints critical success factors. The presentation also provides a perspective on how to ensure that CI remains top-of-mind of Senior Management ensuring long
term sustainability.

Paul Bould
Head of Competitive Intelligence
Bayer Healthcare

__________________________________________________________________________________________________________________________________
11:30-12:00
 Creating visions of new futures in a changing Managed Markets world
With all the uncertainty and changes occurring in Healthcare over the next 4 years as a result of the Patient Protection and Affordable Care Act (PPACA) and
Medicare payment policies, companies are beginning to navigate the uncharted waters of health reform and using scenario planning is an integral part of any
strategic analysis.   Scenario planning is a controlled way to envision different futures, predicting competitor strategies, and anticipating problems that may occur as
a result of the changes.

FCSI will summarize many of the key changes in PPACA, Medicare managed markets and give examples of how you can use this information to as part of strategic
scenario planning exercises to help you navigate your way through the reforms.

Neelima Firth
Vice President, Healthcare Markets
Fletcher/CSI Healthcare Strategies
__________________________________________________________________________________________________________________________________
12:00-1:15
 Networking Luncheon Presentation (Keynote Presentation 12:15-1:00)
Changing Business Models Threaten Existing Intelligence Systems:  Turbulent times are causing business models to rapidly evolve across the healthcare landscape.
However, intelligence systems often fail to keep pace with the change – making organizations vulnerable to missteps and failures! This presentation will share field
research findings regarding the rapid evolution in biopharma, medical device and generics business models that are challenging their BI and CI staff with new
intelligence needs. Case examples will spotlight how some savvy CI and BI professionals are evolving during these dramatic changes in the competitive landscape –
while others fail to adapt and risk extinction.  

Chris Bogan
Chief Executive Officer
Best Practices, LLC

__________________________________________________________________________________________________________________________________
1:15-2:15
 Networking Roundtables/Discussion
(Led by an expert at each table placed throughout exhibition hall. Participants may freely move from one table to another in this open space environment.)
  ROUNDTABLE 1:
 Best Ways to Keep Track on New Targets and Early Programs of Competitors
Carolyn Foster
Senior Associate Director, Technology Assessment, Boehringer Ingelheim Pharmaceuticals, Inc.
  ROUNDTABLE 2:
 CI as a Function of Strategy
Debbie Allison
Senior Director, Global Corporate Licensing, Merck
  ROUNDTABLE 3:
 How CI in R&D Has Evolved and Impacts All Levels in Your Company
Pablo Prados
Senior Director Scientific Competitive Intelligence, Sanofi-Aventis
  ROUNDTABLE 4:
 Monitoring Competitor Pipelines
Friederike Wirtz-Brugger
Associate Director, Scientific Competitive Intelligence, Sanofi-Aventis
  ROUNDTABLE 5:
 Career Paths & Staffing Skills
Marjorie Norman
Director, Worldwide Competitive Intelligence, Pfizer
  ROUNDTABLE 6:
 CI in an Industry Where Everyone Knows Everyone – What is Really Valuable to Our Senior
Leaders
Thorsten Wichtendahl
Senior Manager, Strategic & Competitive Intelligence, Pfizer Australia
  ROUNDTABLE 7:
 Clinical and Commercial CI: How To Use a Combination of the Two For More Effective
Intelligence
Derek L. Johnson
CEO, Aurora WDC

1:15-2:15
Viewing of Poster Exhibits
Chair:
Christopher Perkins
Head of Global Competitive Intelligence - Roche Diagnostics, Diabetes Care
__________________________________________________________________________________________________________________________________
2:15-3:15
 Networking & Refreshments in Exhibition Hall
3:15-3:45
 TRACK A
 The Changing Role of Government in Healthcare
  • Who controls the levers of power impacting the biopharmaceutical industry?
  • How can the industry respond?  How does the industry tell its side of the story?
  • Recap of Healthcare Reform
  • What is the outlook?  What’s next?

Tom Fussaro
Director, Government Relations and Public Policy, Millennium: The Takeda Oncology Company
  TRACK B
 Which technologies to enhance your CI function and which methods to reduce its costs?
The amount of information over the Internet and through communication media exploded over the last decade leaving huge opportunities for
well-prepared corporations to leverage on digital information while avoiding the common pitfalls of information overload, redundant work, and
other time-consuming tasks. The presentation will first describe what are the typical cost structures involved in the overall intelligence workflow.
Then it will describe how your intelligence team can use automation techniques to streamline their information workflow while saving time for
analysis.

Chris Hote
President, Digimind
  TRACK C
 The Automated Discovery of Strategic Business Meaning From Research Repositories
Mr. Seuss will present the opportunities and challenges associated with the creation of systems for the automated analysis and discovery of
strategic meaning from large repositories of market intelligence content.  For example, how do you create systems that assist in finding
meaningful competitive intelligence from volumes of news and market research reports?  What if you could scan thousands of documents in a
few seconds and have the software application summarize your competitors’ corporate strategies, identify which technologies your competitors
are working on, and suggest focus for your further analysis in terms of market trends and competitive threats that are most significant to your
company?  Text analytics enabled with meaning extraction can greatly assist in this process, but using meaning extraction for strategic business
research is a new frontier and there is little guidance out there for practitioners.  Northern Light will present case studies and examples of
meaning extraction at work and describe what works, and does not work, in this emerging technology for competitive intelligence.

C. David Seuss
CEO, Northern Light
  TRACK D
 Mysteries in Commercialization: A Competitive Intelligence Enigma
This presentation will explore:
  • The top three mysteries in commercialization
  • Why CI in commercialization is an enigma
Attendees will learn and take-away:
  • How CI can help solve commercialization mysteries
  • The importance and value of CI in the commercialization process

Michael Martinolich
Vice President and Senior Consultant, Fletcher/CSI Healthcare Strategies
4:15-4:45
 TRACK A
 Generic Medical Devices are Closer than they Appear
People talk about using or trying a generic drug all the time.  We see ads from stores like Walmart and Target offering $4/month discount generic
drugs.  However, we do not hear much talked about generic medical devices and they do exist.  Asthma inhalers and female urinary
incontinence slings are two existing generic medical device products and it is possible that generic medical devices will become more common
in other areas.  Technology development, the regulatory environment, and distribution channels all play a role in the ability of a generic
medical device to enter the market.  In addition, with the forthcoming implementation of healthcare reform legislation, there will be even more
pressure for lower cost medical device options.

Laura Ruth, Ph.D.,
Director, Healthcare, Fuld & Company
  TRACK B
 Innovative Analytics to Track Competitor Landscape  & Trial Developments
  • Succinct trial trackers to monitor trial profiles and updates
  • Customized heatmaps and dashboards to analyze competitor intensity and market segmentation
  • Map of upcoming product milestones
  • Social media tracker to analyze drug-related online commentary
  • Financial analyst and KOL monitors

Laura Farmer
Executive Vice President, The Larvol Group
  TRACK C
 New Pharma Models: how can CI enable Innovation and Diversification in Pharma today
  • Pharma models are changing rapidly and CI contributes to these changes.
  • CI can catalyze the exploitation of Innovation: but definitions of the concept of innovation differ depending on the view point
  • CI contributes to innovation and diversification by identifying novel exploitable concepts and opportunities

Friederike Wirtz-Brugger
Associate Director, Scientific Competitive Intelligence, Sanofi-Aventis
  TRACK D
 mAb biosimilars: The Next Big Thing
CIS Life Sciences’ presentation will explore the potential threats and opportunities posed by the imminent entry of mAb biosimilars:
  • The potential market for mAb biosimilars in the U.S. and Europe
  • Tracking and evaluating organizations developing mAb biosimilars and assessing the threat they pose
  • mAb biosimilars provide an opportunity for new entrants into the biologics space. How can CI expedite the process?

Dr. Rakesh Verma
Director, CIS Life Sciences
DAY 2: (Wednesday, September 22, 2010)
7:15-8:15
 Registration & Networking Breakfast in Exhibition Hall

_________________________________________________________________________________________________________________________________
8:15-8:20
 Chairpersons’ Opening Remarks (Will occur within each separate track session)
8:20-9:15
 TRACK A
 Innovative Biologics, Biosimilars and BioBetters - Which Strategy is Best for Regulated and
Emerging markets?
  • Will a fast follower strategy work in a highly competitive, cost-conscious and payer-centric regulated markets?
  • What kind of direction is needed for successful commercialization of the Follow-on Biologics (FOB)?
  • Lessons learned from the past experience with Follow-on Biologics (FOB).

This discussion will highlight key learnings from the past experience and various recent developments in Biosimilars arena with focus on recent
deals and alliances between US/EU and India/China companies for development and commercialization of biosimilars in regulated and
emerging markets. The discussion will also cover potential impact of different clinical developments and latest commercialization strategies to
provide a real-life prospective on the battle for successful positioning, differentiation and commercialization of the Follow-on Biologics (FOBs).

Moderator:
Dr. Branimir Brankov
Senior Director Stategic Business Intelligence
Merck & Co, Inc.

Panelists:
Peter Simpson
Chairman, Biogenerics Australia

Rich DiCicco
Chairman, Harvest Moon Pharmaceuticals

Dr Anna Mandinova
Professor Harvard Medical School

Margaret Hsiao
CEO & Co-Founder, Harvest Moon Pharmaceuticals USA, Inc.

Stan Bernard
President, Bernard Associates, LLC

Philip Lin Huang
Executive Director, Merck & Co Inc.
  TRACK B
 Enhancing Global CI Networks and Ensuring Global CI Team Development

Deborah Dauber
Associate Director, Competitive Intelligence, Genentech

Pablo Prados
Senior Director Scientific Competitive Intelligence, Sanofi-Aventis

Robert Siegmund
Director Global Commercial Analysis, Actelion

Michelle Castillo
Director of Competitive Intelligence, Baxter Corporation

Valerie Pajak Glyptis
Senior Manager, Business Intelligence & Analytics, APP Pharmaceuticals
  TRACK C
 Key elements to drive HIT and HIE forward so they can meaningfully contribute to EBM and PHC,
in a systems medicine context - is the current HITECH program (from the stimulus package) going
to get us there?

Moderator:
Wayne A. Rosenkrans, Jr., Ph.D.
Distinguished Fellow, MIT Center for Biomedical Innovation
VP Strategic Consulting, Fuld and Co.
Program in Ethics and Systems Medicine, Georgetown University
Chairman and President, Personalized Medicine Coalition
Chief Applications Officer, SciTech Strategies

Panelists:
Ken Buetow
NCI

Kim Slocum
Incoming President of HIMMS and former strategist at AstraZeneca, KS Consulting

Brett Davis
Oracle

Craig McHenry
Director, Competitive Intelligence, Market Analytics, Specialty Care Business Unit, Pfizer Inc.
  TRACK D
 Challenges and Insights in Medical Device & Diagnostics Intelligence

  • Staying on top of critical information
  • Staying ahead of market trends
  • Meeting Emerging Global market CI needs
  • Integrating Competitive Analysis into Strategic Decisions
  • Communicating CI findings to drive stake holder’s decision making.
  • Earning a ‘seat at the table’ during Strategic Discussions
  • Bringing CI from tactic level to strategic level
  • External Challenges potentially impacting MD&D:  Regulatory Approval Process Changes, Medical Device Tax, Healthcare Reform   
    Access to Worldwide procedure data
  • Other items as requested

Christopher Perkins
Head of Global Competitive Intelligence
Roche Diagnostics - Diabetes Care

Kim Szymanowski
Associate Director, Competitive Intelligence
Ethicon, a Johnson & Johnson Company        

Wendy Ye
Principal Competitive Intelligence Specialist
Medtronic
5:45-8:45
 Evening Socializing Events! Casino Gaming, Reception & Networking
 
Sponsored by Fletcher/CSI
10:00-11:00
 Networking & Refreshments in Exhibition Hall
12:40-2:00
 Networking  Luncheon
Have a fantastic lunch and join a table led by one of our speakers and other experts.  Each table will have a specific theme for discussion covering a wide range of
topics that will sure to be of interest to you.  Network and have the opportunity to personally interact with our experts and speakers.
_________________________________________________________________________________________________________________________________
2:00-2:30
 Actioning Intelligence with bespoke Analytical Frameworks
Whilst a sound understanding of CI methodologies is critical to collect timely, accurate and relevant intelligence, useability of the intelligence is fundamental to
delivering the value sought by the end users. In this talk I will explore a number of case studies describing the range of effective outputs that can be generated which
ensure a clear understanding of the competitive situation and can lead to well structured decision making.

Dr. Patrick Romano
Chief Operating Officer
Deallus Group
_________________________________________________________________________________________________
2:30-3:15
 Summary and Closing Remarks from Conference Chairpersons

Dr. Daniel Pascheles
Vice President, Head Global Competitive Intelligence
Merck & Co

Sue Ward
Senior Director, Worldwide Competitive Intelligence
Pfizer

_________________________________________________________________________________________________________________________________
3:15
 Conference Concludes

_________________________________________________________________________________________________________________________________
Participants may choose 1 of 4 concurrent tracks
Participants may choose 1 of 4 concurrent tracks
Participants may choose 1 of 4 concurrent tracks
3:45-4:15
 TRACK A
 Utilizing Probability of Success Analysis to Super-charge CI Insights:  Alzheimer’s Case Study
The session will focus on a methodology for analyzing the Alzheimer’s drug pipeline that incorporates probability of success and the implications
and insights arising from this approach.

Dr. Ben Weintraub
Director of Research, Wolters Kluwer Health
  TRACK B
 The Role and the Necessity of Scientific Intelligence in a Comprehensive Competitive
Intelligence System

Roslyn Potter        
Research Fellow, Vertex Pharmaceuticals Inc
  TRACK C
 Competitive Dynamics in the Vaccines Business: Optimising Approaches to Enhance
Understanding
Vaccines are a highly attractive business for Pharma companies, offering an alternative to reliance on blockbuster sales and mitigation against
impact of patent expiries. Business models in the vaccines industry focus on different selling cycles, decision makers and stakeholders: the
requirements to analyse the competitive dynamics for each model are therefore fundamentally different. This talk will highlight the key
differences between specialised and commodity vaccines and the challenges in therapy areas consisting of two direct competitors and solutions
to overcome these through leveraging external stakeholders and forging strategic partnerships.

Dr Carole Brückler
Business Unit Director, Deallus Group      
  TRACK D
 Managing Asia-Pacific CI Engagements
In today’s evolving competitive landscape, CI groups are increasingly being tasked with obtaining competitive and market intelligence from
countries within the Asia-Pacific region. Prior to diving into research and/or assigning the project to an external CI provider, it is imperative that
the CI group understand the regional attributes, which not only make the Asia-Pacific an opportunity, but provide several challenges as well. As
such, the initial planning and preparation for conducting research in Asia-Pacific necessitate in-depth planning and preparation upfront in order
to ensure successful completion of the engagement.

This presentation will convey the importance of understanding individual country PEST trends including language/deliverable timing
challenges, managing internal client expectations and identifying/working with regional external CI providers. Key takeaways from this
presentation are threefold: (1) to provide an overview of the factors that need to be understood in conducting multi-country CI engagements in
the Asia-Pacific; (2) critical items that must be shared with internal clients to manage expectations; and (3) to provide a foundation for engaging
the appropriate external CI providers.

Sean D. Freston
Managing Director, Asia Pacific, Proactive Worldwide
Participants may choose 1 of 4 concurrent tracks
SEPTEMBER 21-22
HILTON PARSIPPANY HOTEL
NEW JERSEY
4:45-5:15
 TRACK A
 Pharma Manufacturing & Outsourcing Trends
Manufacturing outsourcing is not new to the Pharma Industry... but what is changing? How fast is it changing and what might it look like in the
future?

Mary Ann Sarao
Senior Director, Strategic Business Intelligence, DSM Pharmaceutical Products
  TRACK B
 Who Takes the Physician’s Pulse? – The CI case for working with Medical Science Liaison’s
  • The revised PhRMA code restricting industry gifts has indirectly propelled the role of Medical Science Liaison’s (MSL)
  • Unlike sales rep’s, MSL’s serve strictly as an independent physician advisor and do not foster sales
  • The session will discuss:
  • The increasing industry role of the MSL and the value to CI
  • How does CI approach MSL’s?
  • Value and challenge of building and keeping relationships

Jack Tsai
Principal, Competitive and Technical Intelligence, Genzyme
  TRACK C
 Challenges of Doing CI in Emerging Markets
BRIC nations have emerged as big powerhouses in global economy with rapidly expanding markets and hubs for research and
development.

The challenges associated with conducting CI in emerging markets are very different than in well established markets - the lack of
secondary information is coupled by the cultural nuances.

This interactive and practical session will focus on the challenges of conducting market research in these countries, and provide a
holistic view from companies operating in the  various segments within healthcare - pharma, biotech, devices, healthcare systems, etc.

Corina Turnes
Global Practice Leader Healthcare, Evalueserve
  TRACK D
 “Utilizing Thought Leader Research in Competitive Intelligence – A New Tool for Customizing
Your Analysis”

Through practical case studies, we will demonstrate how to take your competitive intelligence research to a whole new level through the synergy
of BioMedTracker’s powerful pharmaceutical database and MedPredict’s in-depth thought leader interviews.  We will illustrate how our  unique
new tool can help you customize your research for better, more insightful information.

Bobbi Sue Richardson
V.P. Institutional Sales
Sagient Research Syste

Elizabeth Mathews, MBA
CEO
MedPredict Market Research
Participants may choose 1 of 4 concurrent tracks
5:15-5:45
 TRACK A
 Eyes on the Goal: Unmet Medical Need as the Focus of Competitive Intelligence
Success in the pharmaceutical industry hinges on addressing medical needs better than competitors. Out of necessity, CI practitioners often
focus on immediate tactical competitive issues and have limited time to delve deeply into the shortcomings of current therapies. However, for
would-be contributors to a successful competitive strategy, the ability to identify the significant impacts of a disease and spell out a therapy’s
value over alternatives is an essential skill. This presentation will describe efficient methods of developing an unmet need-based competitive
strategy.

Kurt Cannon
Associate Director, Genzyme
  TRACK B
 Undervalued Assets – Internal Resources as Key Intelligence Contributors
Results from the Annual CI/BI Professionals Survey
As the old intelligence axiom goes, 75% of what you need to know lies within your own company. In our fourth annual survey of intelligence
professionals, we examine how effectively CI practitioners harvest intelligence from internal sources.

Current economic conditions and increased uncertainty in the market has resulted in many CI practitioners being asked to do more with less, and
structured internal intelligence programs can be part of the solution.  But are we effectively accessing and leveraging these valuable resources?  
Results and best practices are discussed.

John Rafa
Senior Manager, Business Intelligence, Covance Inc.
  TRACK C
 How Your Advertising Agency Uses Promotional CI; What Strategic Insights Can Be Gained

This talk discusses specific insights that can be gained from promotional CI, from an Advertising Agency’s point of view.  It will demonstrate how
monitoring promotional strategies over time can predict future communication shifts.  It also addresses the value of out-of-category analysis, in
addition to competitor analysis, to create and execute a promotional campaign.

Shelby Rosen
Senior Strategic Planner, Draftfcb HealthCare
  TRACK D
 How to leverage global resources to understand M & A targets and analyze financial data

Pharmaceutical companies are always looking for growth.  Many find it through mergers and acquisitions.   Over the past ten years, the
pharmaceutical industry has experienced over 1,350 mergers across the globe with a value in excess of $700B.  The benefit of an acquisition
and/or mergers are numerous.  Benefits of M & A includes helping a company to increase market share, expand geographic reach, broaden
product offering, gain entry into a high growth areas, and access to new technology platforms.   When selecting an appropriate target, primary
financial intelligence is critical to identifying the best candidate for a successful transaction.   Many CI and Strategic Planning departments are
taking a very active role in helping companies to conduct due diligence on both private and public target candidates.   It is imperative that you
know what to access and evaluate critical financial intelligence on these targeted candidates supported by primary research.  This session will
allow you to gain an in-depth understanding of what to gather and how to analyze critical financial intelligence that can be used to drive
performance.

Jim Caldwell
Senior Consultant, Fletcher/CSI
Participants may choose 1 of 4 concurrent tracks
9:15-10:00
 TRACK A
 Guidelines for Vetting, Hiring, and Managing Pharma CI Vendors

The world of pharma CI is constantly changing, and many different vendors offer their services for human intelligence collection, analytical work,
and other valued added services. Client needs for specific skill sets and levels of experience change from time to time as well.  Session
attendees will learn about a formal vetting and screening process for initial contact and vendor capabilities review, narrowing the vendors to
short list of candidates, selecting several for trial projects and ultimately preparing a preferred vendor list for various types of projects.
Implementation of such a process helps clients to sort through a number of agencies, and select those where they can develop strong working
relationships that meet their internal intelligence needs and standards.

Clifford Kalb
President
C. Kalb & Associates, LLC
  TRACK B
 Ways to Track Technologies and Trends in Technologies, Technology Licensing, and Technology
Deals/Collaborations.

Moderator:
Carolyn Foster
Sr. Associate Director, Technology Assessment, Boehringer Ingelheim

Panelists:
Birgit Rubensdoerffer
Boehringer Ingelheim

Indra Sethy-Coraci
Principal Analyst, Boehringer Ingelheim

JJ Owen
Director, Scientific & Competitor Analysis, Millennium Pharmaceuticals
  TRACK C
 Realizing the potential for EBM and CER, in the context of PHC and how we get to a Learning
Healthcare System which will reduce the cost of care while increasing the quality of care.

Moderator:
Wayne A. Rosenkrans, Jr., Ph.D.
Distinguished Fellow, MIT Center for Biomedical Innovation
Program in Ethics and Systems Medicine, Georgetown University
Chairman and President, Personalized Medicine Coalition
VP Strategic Consulting, Fuld and Co.
Chief Scientific Advisor, Expertech Solutions
Chief Applications Officer, SciTech Strategies

Panelists:
Felix Frueh
Medco

Sheila Walcoff
Partner, McDermott Will & Emery LLP
former Chief Counsel to Secretary Leavitt, HHS

Craig McHenry
Director, Competitive Intelligence, Market Analytics, Specialty Care Business Unit, Pfizer Inc.
  TRACK D
 Case Studies and Best Practices in Partnering with a Consultant Firm

Marjorie Norman
Director, Worldwide Competitive Intelligence, Pfizer

Jamie Denison-Pender
Managing Director, CIS Life Sciences
Participants may choose 1 of 4 concurrent tracks
11:00-11:40
 TRACK A
 Unlocking the Competitive Intelligence Potential of Social Networks and Social Media
This programme outlines how social media can be used in a CI setting using practical examples and a case study.  The agenda for the
discussion includes: What is Social Media,  Why is it important, Use  in Pharma, Red Herrings, Practical Examples,  Biogenerics - A Case Study.

Beth Elliott
Vice President, Healthcare, Europe,Fuld & Co.
  TRACK B
 "Cause and Effect" - How to Integrate CI Into Decision Making, in a Way that Cannot Be Ignored

CI often becomes detached from the overall strategy of many large pharmaceutical companies - it has to fight hard  to get a permanent seat on
the "Product Team",  it's value is questioned, people sneer at it's inability to prove ROI …  it just struggles to embed and get itself integrated into
the key business processes. To compound the misery, achieving a coordinated range of inputs to support decision is difficult too, due to
organisational structures/silo's and budget "turf wars". Claudio will introduce an approach, popular in other industries but less so in pharma',  
which makes CI central to decision making, driving real collaboration in immediate support of the brand/product. This is a case study of how to
deliver measurable impacts and how to work collaboratively with your Marketing team.

Claudio D’Ambrosio, PhD, MSc
Business Unit Director, Deallus Group
  TRACK C
 Responder Panel
Responder Panel will provide reactions and analysis on the preceding panel discussions.

Moderator:
Wayne A. Rosenkrans, Jr., Ph.D.
Distinguished Fellow, MIT Center for Biomedical Innovation
VP strategic Consulting, Fuld and Co.
Program in Ethics and Systems Medicine, Georgetown University
Chairman and President, Personalized Medicine Coalition
Chief Applications Officer, SciTech Strategies
  TRACK D
 TBA
Participants may choose 1 of 4 concurrent tracks
11:40-12:40
 TRACK A
 Bringing Competitive Insights into New Product Planning and Business Development

Chandra Ramanathan        
Director, Commercial Development Oncology, Bayer HealthCare Pharmaceuticals

Debbie Allison
Senior Director, Global Corporate Licensing, Merck

Thomas Han
Senior Director, Strategic Marketing, Business Analysis, Biovail

Sanjiv Sharma
Vice President of Commercial Affairs, Nicox

Rachid Benhamza        
Director Product Management Commercial Operations, Helsinn Healthcare S.A.

Michael Heerde
Head Strategy & Business Development, Bayer HealthCare China

Jeff Beeny
Senior Manager of Business Intelligence, Thermo Fisher Scientific
  TRACK B
 CI & Market Research: What Degree of Collaboration or Integration Works Best?

Robert Siegmund
Director of Global Commercial Analytics, Actelion Pharmaceuticals Ltd

Sandipa Dublish
Director Global Market Research, Eisai

Gretchen Moss        
Senior Manager, Business Services, Merial

Gerald Kunze        
Associate Director, Market Research & Business Analytics, CSL Behring

Mark Edelstein
Senior Director, Market Research, Lundbeck

JJ Owen
Director, Scientific & Competitor Analysis, Millennium Pharmaceuticals
  TRACK C
 Turning Regulatory Intelligence into Competitive Advantage
1.    Introduction to the panel
2.    Defining Regulatory Intelligence
3.    Why regulatory intelligence is important to the regulated medical product industry
4.    Brief discussion of available tools
5.    Case Studies

(To continue with a lunch table discussion)

Jennifer Breen Andreasson
Worldwide Regulatory Policy and Intelligence, Pfizer

Linda Bowen        
Director Regulatory Intelligence and Policy, Sanofi-Aventis

Susan Laufer
Director, Strategic Research, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
  TRACK D
 From Local to Regional to Global…Commercialization to Fit the New World Economy  
The pharmaceutical world is evolving through social, economic, regulatory and political trends that are influencing how products are
commercialized locally, regionally and globally.  Pharmaceutical companies are shifting strategies and resources to account for an estimated
10% to 14% growth in geographic areas of the world, such as APAC, EMEA and LATAM.  What do you need to know to support
commercialization in this new environment?  To help you navigate this landscape the four regions of the world, NORAM, LATAM, EMEA and
APAC, will be highlighted and discussed.  This panel discussion is designed to foster thought and discussion on the benefits, pitfalls and benefits
of local, regional and global commercialization and relevant CI application.

Each region will be presented by a panel well versed in current and future global and regional commercialization trends and nuances.  
Discussion will focus on:
  • The necessary relationships and communications with corporate operations/functions needed to commercialize a global brand
  • The difficulties of assessing commercial opportunities within the region in relationship to the company’s global strategy
  • The pitfalls and pearls in building and implementing the development and commercialization plans for a global brand in the region
  • What contribution regional commercialization plans can make to the global commercialization plan

Hosted by: Erik Glitman
Managing Director, Fletcher/CSI

Panelists TBA
Eduardo Flores Bemudez (invited)
Specialist for Competitive Intelligence, Bayer Schering Pharma AG
Chair of Board of Directors, Society for Competitive Intelligence Professionals (SCIP)

Additional Panelists TBA
Participants may choose 1 of 4 concurrent tracks
PHARMA CI CONFERENCE TRACKS
The Pharma CI Conference provides four separate conference tracks to allow attendees to customize their experience.  Each track will be lead by one the
premier leaders in the industry to facilitate a fruitful and lively discussion.  Please feel free to choose topics among the four concurrent tracks.  There is no
need to pre-select - make your decisions on site!
TRACK A LEADER
 Dr. Daniel Pascheles
Vice President, Head Global Competitive Intelligence
Merck & Co
TRACK B LEADER
 Sue Ward
Senior Director, Worldwide Competitive Intelligence
Pfizer
TRACK C LEADER
 Dr. Martha Matteo
Fellow and past President, SCIP
Former Director, Knowledge Management of R&D Planning, Boehringer Ingelheim
TRACK D LEADER
 TBD